“Breast cancer with a good prognosis in elderly patients: is sentinel lymph node biopsy still justified?”

Cirugia espanola Pub Date : 2026-10-01 Epub Date: 2026-05-20 DOI:10.1016/j.cireng.2026.800351

Carlota López Domínguez, Alejandra García Novoa, Benigno Acea Nebril, Sergio Rodríguez Rojo, Aloia Guerreiro Caamaño

{"title":"“Breast cancer with a good prognosis in elderly patients: is sentinel lymph node biopsy still justified?”","authors":"Carlota López Domínguez, Alejandra García Novoa, Benigno Acea Nebril, Sergio Rodríguez Rojo, Aloia Guerreiro Caamaño","doi":"10.1016/j.cireng.2026.800351","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>In older women with early-stage, hormone receptor-positive breast cancer, the value of sentinel lymph node biopsy (SLNB) has been questioned due to its limited prognostic and therapeutic impact.</div></div><div><h3>Objective</h3><div>To evaluate the usefulness of SLNB in this population.</div></div><div><h3>Methods</h3><div>A systematic review was conducted in accordance with the PRISMA 2020 guidelines. Studies published between 2014 and 2024 were searched in PubMed, Cochrane Library, and Google Scholar, analyzing the impact of SLNB in women ≥60 years of age with cT1–T2N0, RH+, HER2– tumors undergoing primary surgery, and we performed a meta-analysis by subgroups focused on homogeneous domains.</div></div><div><h3>Results</h3><div>Of the 8,396 studies identified, 35 met the inclusion criteria. Omitting SLNB did not affect survival or increase recurrences, reducing the indication for adjuvant therapies.</div></div><div><h3>Conclusion</h3><div>In older women with low-risk early breast cancer, omitting SLNB is safe and does not compromise survival.</div></div>","PeriodicalId":93935,"journal":{"name":"Cirugia espanola","volume":"104 10","pages":"Article 800351"},"PeriodicalIF":0.0000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cirugia espanola","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173507726001560","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

In older women with early-stage, hormone receptor-positive breast cancer, the value of sentinel lymph node biopsy (SLNB) has been questioned due to its limited prognostic and therapeutic impact.

Objective

To evaluate the usefulness of SLNB in this population.

Methods

A systematic review was conducted in accordance with the PRISMA 2020 guidelines. Studies published between 2014 and 2024 were searched in PubMed, Cochrane Library, and Google Scholar, analyzing the impact of SLNB in women ≥60 years of age with cT1–T2N0, RH+, HER2– tumors undergoing primary surgery, and we performed a meta-analysis by subgroups focused on homogeneous domains.

Results

Of the 8,396 studies identified, 35 met the inclusion criteria. Omitting SLNB did not affect survival or increase recurrences, reducing the indication for adjuvant therapies.

Conclusion

In older women with low-risk early breast cancer, omitting SLNB is safe and does not compromise survival.

查看原文本刊更多论文

“老年乳腺癌预后良好：前哨淋巴结活检是否仍然合理？”

目的：评价SLNB在该人群中的应用价值。方法：根据PRISMA 2020指南进行系统评价。我们在PubMed、Cochrane Library和谷歌Scholar中检索了2014年至2024年间发表的研究，分析了SLNB对接受原发性手术的年龄≥60岁的cT1-T2N0、RH+、HER2-肿瘤患者的影响，并对同质域进行了亚组荟萃分析。结果：在8396项研究中，35项符合纳入标准。忽略SLNB不影响生存或增加复发，降低了辅助治疗的适应证。结论：对于患有低风险早期乳腺癌的老年妇女，省略SLNB是安全的，并且不会影响生存。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cirugia espanola

自引率

0.00%

发文量